Torsdag 13 November | 02:45:19 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-08-20 08:30 Kvartalsrapport 2026-Q2
2026-05-07 N/A Årsstämma
2026-05-07 08:30 Kvartalsrapport 2026-Q1
2026-02-20 08:30 Bokslutskommuniké 2025
2025-11-27 08:30 Kvartalsrapport 2025-Q3
2025-10-10 - Extra Bolagsstämma 2025
2025-08-11 - Kvartalsrapport 2025-Q2
2025-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2025-05-07 - Årsstämma
2025-05-07 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 - Årsstämma
2023-05-03 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-24 - Extra Bolagsstämma 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-17 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-06-04 - Årsstämma
2019-05-23 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Lumito är ett svenskt bolag som utvecklar och marknadsför system för vävnads- och biomarköranalys inom digital patologi, byggda på uppkonverterande nanopartikelteknik. Bolaget riktar sig till vårdinrättningar, forskning och läkemedelssektorn. Bolaget bildades under 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-11-11 22:30:00

THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE REGISTRATION UNDER APPLICABLE REGULATIONS.

Lumito AB (publ) ("Lumito" or the "Company") has completed the rights issue of units consisting of shares and warrants with preferential rights for existing shareholders (the "Rights Issue"), which the Board of Directors resolved on September 9, 2025, and which was approved by the Extraordinary General Meeting on October 10, 2025. In accordance with the guarantee agreements entered into in connection with the Rights Issue, the Board of Directors resolved on November 11, 2025, on a directed share issue of units to the guarantors in the Rights Issue (the "Compensation Issue"). The subscription price in the Compensation Issue amounts to the same subscription price as in the Rights Issue, SEK 0.025 per share, and payment is made by set-off of the guarantors' claims regarding guarantee compensation. In total, 18,699,984 shares and 12,466,656 warrants of series TO7 will be allotted to the guarantors in the Compensation Issue.

The rights issue carried out by Lumito AB was secured through subscription commitments and guarantee commitments to approximately 60 percent. For underwriting guarantees, a consideration of fifteen (15) percent of the underwritten amount can be paid in cash or seventeen (17) percent of the underwritten amount in units, with the same terms and conditions as for units in the Rights Issue. In view of this, the Board of Directors has, based on the authorization granted by the Extraordinary General Meeting on October 10, 2025, resolved on the Compensation Issue, which in total comprises 18,699,984 shares and 12,466,656 warrants of series TO7. The subscription price amounts to SEK 0.025 per share, corresponding to the subscription price in the Rights Issue.

The reason for the deviation from the shareholders' preferential rights in the Compensation Issue is to fulfil the Company's contractual obligation towards the guarantors. The Board of Directors believes that it is to the advantage of the Company's financial position to take advantage of the opportunity to pay the guarantee fee in the form of units instead of through cash payment as this has a positive effect on the Company's liquidity. Payment in the Compensation Issue is made by set-off of the guarantors' claim for guarantee compensation. The subscription price in the Compensation Issue was negotiated at arm's length in connection with the procurement of the guarantee commitments, which was done in consultation with the financial advisor and after an analysis of customary market factors. The Board of Directors' assessment is that, against this background, the subscription price is market-secured.

Shares, share capital and dilution
Through the Compensation Issue, and after registration of the Rights Issue, the total number of shares in the Company will increase by 18,699,984 shares, from 1,701,748,167 shares to 1,720,448,151 shares, corresponding to a maximum dilution effect of 1 percent of the number of shares and votes in the Company. The share capital will increase by approximately SEK 467,499.600, from approximately SEK 42,543,704.175 to SEK 43,011,203.775.

Advisers
Mangold Fondkommission AB is acting as financial advisor and Advokatfirman Lindahl KB is acting as legal advisor to Lumito in connection with the Rights Issue.